Teva And Regeneron Announce Global Collaboration To Develop And Commercialize Fasinumab, An Investigational NGF Antibody For Chronic Pain JERUSALEM & TARRYTOWN, N.Y.-- --Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. announced today a global1 agreement to develop and commercialize fasinumab, Regeneron's investigational NGF antibody in Phase 3 clinical development for osteoarthritis pain and in Phase 2 development for chronic low back pain. Under the terms of the agreement, Teva will pay Regeneron $250 million upfront and share equally in the global1 commercial value, as well as ongoing research and development costs of approximately $1 billion.
http://ift.tt/2cZPuWA
No comments:
Post a Comment